Immune Thrombocytopenia Induced by Sintilimab in Lung Cancer:
A Case Report and Literature Review.
10.3779/j.issn.1009-3419.2023.102.32
- Author:
Jingjing CAI
1
;
Guangxia YANG
1
;
Xuemei ZHANG
1
;
Linlin LIU
1
;
Mei YAN
1
Author Information
1. Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Jining Medical University, Jining 272029, China.
- Publication Type:Journal Article
- Keywords:
Immune checkpoint inhibitors;
Immune thrombocytopenia;
Immune-related adverse events;
Lung neoplasms;
Sintilimab injection
- MeSH:
Humans;
Purpura, Thrombocytopenic, Idiopathic/drug therapy*;
Lung Neoplasms/drug therapy*;
Thrombocytopenia/chemically induced*;
Antibodies, Monoclonal, Humanized/adverse effects*
- From:
Chinese Journal of Lung Cancer
2023;26(9):717-720
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors (ICIs) show unique advantages in the treatment of lung cancer, making the treatment of lung cancer enter the era of immunotherapy, but ICIs will also have adverse reactions, and the incidence of immune-induced hematological toxicity is not very high. Immunotherapy-induced thrombocytopenia is a rare adverse event.We report one case of thrombocytopenia induced by ICIs and review the literature on thrombocytopenia associated with ICIs and discuss the clinical features, possible mechanisms, and optimal treatment.
.
